Draximage makes business moves
Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It
Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It also closed the acquisition of a pharmaceutical manufacturing facility in Quebec that will become its permanent headquarters.
In the first agreement, Draximage signed a deal with Molecular Targeting Technology (MTTI) of Malvern, PA, to develop, manufacture, and market new imaging agents. The first potential product covered by the relationship is Amiscan, a formulation of technetium-99m glucarate being developed for the early diagnosis of acute myocardial infarction. Preliminary results with the agent indicate that it could be used to diagnose and localize myocardial infarct within a few hours of onset.
In the other deal, Draximage's parent company, Draxis Health, completed the acquisition from IVX BioScience of a manufacturing facility in Kirkland, Quebec, that formerly was used by pharmaceutical giant Burroughs Wellcome. The facility will become the headquarters for Draximage and will assume manufacturing responsibilities for other Draxis products. Draximage is developing a range of peptide-based targeted radiopharmaceuticals for applications such as deep vein thrombosis, oncology, and lung and kidney scans (SCAN 2/18/98).
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
